Guggenheim Capital’s CARDIUM THERAPEUTICS INC NEW CXM Stock Holding History

Guggenheim Capital’s Portfolio CXM Stock Details CXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-2,952	Closed	-$4K	–	3261
2013 Q2	$4K	Buy	+2,952	New	+$5.31K	﹤0.01%	3030

Other funds holding CXM

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Canada Life Winnipeg, Manitoba, Canada $55.8B AUM 26.04% 1-Year Est. Return

Guggenheim Capital's CXM Position: Q3 2013 in Review

Guggenheim Capital sold out of CARDIUM THERAPEUTICS INC NEW (CXM) in Q3 2013, closing a stake of 2,952 shares — an estimated $4K sold.

Guggenheim Capital first reported a position in CXM in Q2 2013 and held it in 1 quarter. The position peaked at $4K in Q2 2013. 8 funds tracked by Wall St. Rank hold CXM as of Q3 2013.

Guggenheim Capital reported no remaining CARDIUM THERAPEUTICS INC NEW position as of Q3 2013 after selling out during the quarter.
Guggenheim Capital sold 2,952 CARDIUM THERAPEUTICS INC NEW shares in Q3 2013, an estimated $4K.
Guggenheim Capital first reported a position in CARDIUM THERAPEUTICS INC NEW in Q2 2013 and held it in 1 quarter.
Guggenheim Capital's CARDIUM THERAPEUTICS INC NEW position peaked at $4K in Q2 2013.
8 funds tracked by Wall St. Rank held CARDIUM THERAPEUTICS INC NEW as of Q3 2013.

Based on Guggenheim Capital's 13F filing for Q3 2013, filed 14 Nov 2013.